Hygromycin B Premix Veterinary Grade API is a fermentation-derived aminoglycoside obtained from Streptomyces hygroscopicus and supplied as two standard models: HYG-PMX-80 and HYG-PMX-200, where the numeric suffix denotes nominal hygromycin B activity of 80 g/kg and 200 g/kg, respectively, on a calcium carbonate/dextrin carrier. The active molecule has CAS 31282-04-9, molecular formula C20H37N3O13, and molar mass 527.53 g/mol. The premix is released for downstream formulation into tablets, capsules, oral powders, granules, medicated premixes, and oral solutions; a sterile parenteral grade requires additional purification, depyrogenation, and carrier removal. The product is not sterile and is not represented as a direct injectable API. Release documentation includes high-performance liquid chromatography assay with detection at 210 nm against a hygromycin B reference standard, loss on drying per USP <731>, residue on ignition per USP <281>, and microbial enumeration per USP <61> and USP <62>. The carrier system influences powder flow and blend uniformity; therefore the premix is specified for feed and non-sterile oral dosage forms. Injectables require a carrier-free hygromycin B base or sulfate with endotoxin control per USP <85> and subvisible particle evaluation per USP <788>.

What Limits Hygromycin B in Parenteral Dosage Forms?

The principal limitation is the carrier. The premix grade contains insoluble calcium carbonate/dextrin particles that, upon reconstitution, exceed the subvisible particle limits of USP <788> for large-volume injections. A carrier-free hygromycin B substance with a measured particle count below 25 particles/mL at the 10 µm threshold would be required for a candidate injection. Ototoxicity and nephrotoxicity are class-specific aminoglycoside effects, and published data for parenteral hygromycin B in target veterinary species are limited; the premix does not carry a safety claim for systemic administration. Aqueous stability is pH-dependent: the glycosidic linkages hydrolyze below pH 3.0 and above pH 8.5 at 25 °C over 24 h. Injectable compounding would therefore use citrate or phosphate buffers in the range pH 5.5–7.0. Hygromycin B can form inactive complexes with β-lactam antibiotics if mixed in a single infusion line; visible precipitation is reported within 15 min in lactated Ringer's solution. Autoclaving at 121 °C for 15 min is not recommended for the premix because the dextrin component undergoes Maillard browning in the presence of reducing sugars and amino impurities.

For sterile filtration of a carrier-free solution, a 0.22 µm polyethersulfone membrane is used, but only after endotoxin removal by tangential flow filtration or activated carbon. The premix is not processed through endotoxin-reduction steps; therefore its use in injectables would require a validated purification train. No claim is made for direct intravenous, intramuscular, or subcutaneous injection of HYG-PMX-80 or HYG-PMX-200.

Analytical release of hygromycin B premix is complicated by the weak chromophore of the aminoglycoside core. Reverse-phase HPLC with UV detection at 210 nm is acceptable only when the method has been validated for specificity against fermentation by-products. Many production laboratories use post-column derivatization with o-phthalaldehyde and fluorescence detection; system suitability follows USP <621> with a tailing factor not more than 2.0, theoretical plates not less than 2000, and injection precision below 2.0% RSD. The assay is performed on a 150 mm × 4.6 mm C18 column maintained at 30 °C with a mobile phase of phosphate buffer and methanol at 1.0 mL/min. Fermentation-derived batch-to-batch variance is controlled by blending to a target potency; release data from production lots typically show assay RSD below 2.5% for the blended premix.

For dry granulation and direct compression, the premix is characterized by powder flow properties measured per USP <1174>. Typical values for HYG-PMX-80 are bulk density 0.45–0.65 g/mL, tapped density 0.60–0.80 g/mL, Hausner ratio 1.25–1.35, and Carr index 18–25%. Particle size distribution by sieve analysis per USP <786> is controlled with no more than 10% retained on 180 µm and no more than 50% passing 75 µm for direct compression. The material is pre-dried at 40 °C for 4 h in a fluid-bed dryer with inlet air dew point below -10 °C when ambient RH exceeds 60%, because moisture uptake above 4.0% increases the Hausner ratio above 1.35 and causes sticking on rotary tablet press punches. Tablet compression on a rotary press with 12 stations and a maximum pre-compression force of 5 kN produces acceptable tablets when final hardness is 60–100 N and disintegration per USP <701> is below 15 min in 0.1 M HCl. Capsule filling on an automatic dosator machine requires colloidal silicon dioxide at 0.5–1.0% w/w due to static charge and rat-holing. The blend is passed through a 500 µm cone mill before encapsulation, and water activity is maintained below 0.60 to limit microbial growth.

For oral sachet powders, the final blend is filled by weight into foil-lined sachets under 25% RH. Finished blend assay uniformity per USP <905> is tested with acceptance value not more than 15.0. In production-scale transfer through a 6 m flexible screw conveyor, the active assay remains within 90–110% of label claim when the carrier particle size is within 75–250 µm and the conveyor angle does not exceed 45°. A wet granulation process is not recommended because water addition forms a sticky mass at liquid-to-solid ratio below 0.15; if wet granulation is unavoidable, the granulation end-point is determined by power consumption on a 10 L high-shear granulator at impeller speed 300 rpm and chopper 1500 rpm, with granule size 250–850 µm.

Release and stability testing of finished oral tablets includes dissolution per USP <711> in 900 mL of 0.01 M hydrochloric acid at 37 °C and 50 rpm paddle speed. The dissolution Q value is set at 80% in 30 min for immediate-release formulations; however, published data for this specific configuration is limited. A stability-indicating method must separate hygromycin B from its acid hydrolysis products; forced degradation at 0.1 M HCl, 0.1 M NaOH, 3% H2O2, and 80 °C dry heat shows that oxidation produces a faster potency loss than thermal stress. The mass balance requirement is 95–105% in forced degradation studies.

When Hygromycin B Premix Is Used in Oral Solution and Drinking Water Systems

For oral solution and drinking water medication, the premix is dispersed in dechlorinated water. Chlorinated mains water oxidizes the aminoglycoside; free chlorine above 0.2 mg/L produces a measurable potency loss of 2–3% over 8 h in controlled laboratory trials. Stock solutions are prepared at 1–5 g/L active concentration and filtered through a 10 µm in-line polypropylene filter to remove carrier particles before entering nipple drinkers or dosing syringes. Solution pH is adjusted to 6.0–6.5 with citric acid monohydrate. The solution is considered stable for 24 h at 20–25 °C; refrigerated storage at 2–8 °C extends the working period to 72 h, but published data for this specific configuration is limited. Phosphate buffers above 50 mM should be avoided because precipitation with calcium and magnesium ions in hard water can block drinker lines. The premix is not suitable for nebulization or metered-dose inhalation because the carrier-derived residual aerodynamic particle size distribution falls outside the 1–5 µm range required for pulmonary deposition.

Comparative Stability and Potency Loss in Multivalent Feed Premixes

Compared with neomycin sulfate and streptomycin sulfate premixes, hygromycin B premix has a narrower anthelmintic indication and a pH-labile glycosidic structure. In the United States, medicated feed use of hygromycin B is regulated under 21 CFR 558.274; formulators must verify current approval conditions, because use levels and withdrawal periods are subject to change. Unlike ionophores such as monensin, hygromycin B is not effective against coccidia. Unlike avermectins, it does not act on glutamate-gated chloride channels; its ribosomal binding site confers a different resistance profile. Hygromycin B phosphotransferase, the resistance marker used in cell culture, reduces antimicrobial activity in organisms expressing the enzyme; this is distinct from the acetyltransferase and adenyltransferase mechanisms observed with neomycin and streptomycin. In multivalent premixes, hygromycin B should not be blended with bentonite clay above 2% w/w, because cation-exchange binding reduces the free active fraction. It is also incompatible with sodium hypochlorite, potassium permanganate, and strong anionic surfactants. Feed pelleting at temperatures above 85 °C for more than 60 s can accelerate degradation; published data for this specific configuration is limited.

HYG-PMX-200 is used for high-potency premixes where lower carrier dilution is required; it is diluted with dry feed ingredients in a ribbon mixer to a target 12 g/ton complete feed. The dilution step involves geometric mixing: a 1:10 premix is first prepared in a V-blender, then incorporated into the final feed. Segregation of the high-potency model is greater because of the higher active-to-carrier density difference; therefore batch uniformity in the finished feed is tested by sampling 10 locations per 2 ton batch and requires an assay RSD below 5.0%.

Compared with hygromycin B used as a cell-culture selection agent, the veterinary premix has a lower purity requirement for host-cell proteins, endotoxin, and residual solvents. The cell-culture grade is lyophilized, endotoxin-tested, and supplied in sterile vials; the premix is a bulk feed-grade powder and should not be substituted for molecular biology applications. The product should not be mixed with β-lactam antibiotics in solution, anionic polysaccharides, or strong alkalis. The operational boundary is non-sterile oral and feed use only; any use outside this boundary requires a qualified purification and sterilization process with endotoxin control per USP <85>.